Related Experiment Video
Updated: Nov 16, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Data-driven FDG-PET subtypes of Alzheimer's disease-related neurodegeneration
Fedor Levin1, Daniel Ferreira2, Catharina Lange3,4
1German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Rostock, Germany.
Background:
Previous research has described distinct subtypes of Alzheimer's disease (AD) based on the differences in regional patterns of brain atrophy on MRI. We conducted a data-driven exploration of distinct AD neurodegeneration subtypes using FDG-PET as a sensitive molecular imaging marker of neurodegenerative processes.
Methods:
Hierarchical clustering of voxel-wise FDG-PET data from 177 amyloid-positive patients with AD dementia enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI) was used to identify distinct hypometabolic subtypes of AD, which were then further characterized with respect to clinical and biomarker characteristics. We then classified FDG-PET scans of 217 amyloid-positive patients with mild cognitive impairment ("prodromal AD") according to the identified subtypes and studied their domain-specific cognitive trajectories and progression to dementia over a follow-up interval of up to 72 months.
Results:
Three main hypometabolic subtypes were identified: (i) "typical" (48.6%), showing a classic posterior temporo-parietal hypometabolic pattern; (ii) "limbic-predominant" (44.6%), characterized by old age and a memory-predominant cognitive profile; and (iii) a relatively rare "cortical-predominant" subtype (6.8%) characterized by younger age and more severe executive dysfunction. Subtypes classified in the prodromal AD sample demonstrated similar subtype characteristics as in the AD dementia sample and further showed differential courses of cognitive decline.
Conclusions:
These findings complement recent research efforts on MRI-based identification of distinct AD atrophy subtypes and may provide a potentially more sensitive molecular imaging tool for early detection and characterization of AD-related neurodegeneration variants at prodromal disease stages.
Insights
This study identified three distinct subtypes of Alzheimer's disease (AD) using FDG-PET imaging. These subtypes show different neurodegeneration patterns and cognitive decline trajectories, aiding early AD detection.
Area of Science:
- Neuroimaging
- Molecular Imaging
- Neurology
Background:
- Alzheimer's disease (AD) exhibits distinct subtypes based on brain atrophy patterns observed in MRI scans.
- This research explores AD neurodegeneration subtypes using fluorodeoxyglucose-positron emission tomography (FDG-PET), a sensitive marker for neurodegenerative processes.
Purpose of the Study:
- To identify distinct hypometabolic subtypes of Alzheimer's disease (AD) using FDG-PET data.
- To characterize these subtypes based on clinical and biomarker data.
- To examine cognitive trajectories and dementia progression in prodromal AD subtypes.
Main Methods:
- Hierarchical clustering of voxel-wise FDG-PET data from 177 amyloid-positive AD dementia patients.
- Characterization of identified subtypes using clinical and biomarker data.
- Classification and analysis of FDG-PET scans from 217 amyloid-positive mild cognitive impairment patients.
Main Results:
- Three hypometabolic AD subtypes were identified: "typical" (posterior temporo-parietal, 48.6%), "limbic-predominant" (memory-predominant, 44.6%), and "cortical-predominant" (executive dysfunction, 6.8%).
- Prodromal AD subtypes mirrored AD dementia subtypes.
- Subtypes showed differential cognitive decline courses.
Conclusions:
- FDG-PET imaging reveals distinct AD neurodegeneration subtypes.
- These findings complement MRI-based atrophy subtype research.
- FDG-PET may offer a sensitive tool for early AD detection and characterization of neurodegeneration variants.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment

![Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58641.jpg&w=3840&q=50)